No registrations found.
ID
Source
Brief title
Health condition
Hartfalen, myocardinfarct, genetica, biomarkers, bioinformatica, heart failure, myocardial infarction, genetics, bioinformatics, pathway
Sponsors and support
Department of Cardiology, Division Heart & Lungs
University Medical Center Utrecht
Room E03.511
P.O. Box 85500
3508 GA Utrecht
The Netherlands
care)
Intervention
Outcome measures
Primary outcome
Time till first hospitalization for heart failure or heart failure related mortality.
Secondary outcome
1. Reinfarction;
2. Stent thrombosis;
3. Arrhythmias;
4. Cardiac mortality (including sudden cardiac arrest survivors);
5. All-cause mortality;
6. Combination of all endpoints.
Background summary
Rationale:
Heart failure (HF) is a major medical problem of the Western world, carrying a high morbidity, mortality and economic burden. An ischemic etiology such as an acute myocardial infarction (MI) underlies the development of HF in 70% of all cases. A substantial part of the susceptibility to develop ischemic HF is thought to be largely genetically based. However, genetic variants causing HF have only been identified in some families suffering from non-ischemic HF.
Objective:
The main aim of the current study is to identify novel pathophysiological pathways associated with the development of post-MI HF using genome-wide data and innovative bioinformatics approaches.
Study design:
The study is a multi-center, prospective, longitudinal, observational study.
Study population:
Patients admitted for treatment of a myocardial infarction are considered for inclusion.
Main study parameters/endpoints:
The primary outcome is the incidence of hospitalizations for heart failure. Secondary endpoints include reinfarction, stent thrombosis, arrhythmias, cardiac mortality, all-cause mortality and the combination of all these endpoints.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
This is an observational study. Participants will not be exposed to any risks associated with participation to the current study. Participants will not have any advantages or disadvantages by participating in the current study.
Study objective
The main aim of the current study is to identify novel pathophysiological pathways associated with the development of heart failure after an acute myocardial infarction.
Study design
Total follow-up duration is 3-5 years.
Intervention
N/A
F.W. Asselbergs
Department of Cardiology, Division Heart & Lungs
University Medical Center Utrecht
Room E03.511
Utrecht 3508 GA
The Netherlands
f.w.asselbergs@umcutrecht.nl
F.W. Asselbergs
Department of Cardiology, Division Heart & Lungs
University Medical Center Utrecht
Room E03.511
Utrecht 3508 GA
The Netherlands
f.w.asselbergs@umcutrecht.nl
Inclusion criteria
1. Patients admitted with an acute myocardial infarction and candidates for primary PCI. A diagnosis of acute myocardial infarction is defined by chest pain suggestive for myocardial ischemia for at least 30 minutes with a time from onset of symptoms of less than 24 hours before hospital admission and an ECG with ST segment elevation of more than 0.1mV in 2 or more leads;
2. Minimum age 18 years;
3. Verbal followed by written informed consent.
Exclusion criteria
1. Presence of other serious medical conditions with a life expectancy of less than 6 months;
2. Unwilling to sign informed consent.
Design
Recruitment
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL2613 |
| NTR-old | NTR2741 |
| CCMO | NL29888.042.10 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |
| OMON | NL-OMON34692 |